Texas based XBiotech enrolled the first patient in a Phase III trial of Xilonix by Dr. Eric Roeland at UC San Diego’s Moores Cancer Center. The first True Human(TM) antibody, Xilonix exerts its action by blocking the chronic inflammatory processes associated with cancer and thereby limits the growth and metastatic potential of cancer. The positive effects exerted by regular intake of Xilonix helps in delaying complications like cancer associated cachexia.
The phase III trial of Xilonix is formulated to study the health benefits of the drug in late stage colo-rectal cancer in terms of improving survival and management of cancer cachexia. The randomized controlled study will be first conducted in United States to study the effect of Xilonix on survival and a total of 650 patients will be enrolled. It is expected that the study will be completed by late 2014.
A higher than normal survival period was observed in refractory cancer patients in a previous study conducted at MD Anderson Cancer Research Center, Texas with a substantial improvement in lean body mass observed in almost 33% of the patients. Almost all the patients reported improvement in the functional status, energy levels, weight gain and overall improved quality of life.
The President and CEO of XBiotech defined Xilonix and its potential effectiveness in these words:
“This is a very unique anti-cancer agent that we believe inhibits tumor growth and facilitates physical and emotional recovery from the disease. Xilonix has demonstrated the potential to prolong survival in patients considered refractory to all treatments. This represents a very important therapy.”
About True Human Antibodies:
True Human Antibodies are more effective, tolerable and safer when compared to traditional therapeutic antibodies. The higher tolerance and safety profile is attributed to the blinding action of True Human Antibodies on immune cells. THA are the new generation antibody therapeutics with higher efficacy and potential benefits over previous therapeutic antibodies.
XBiotech is counted among the pioneers in developing highly effective and safe therapeutic antibodies. The lead product of the company exerts its action by blocking the mediators of chronic inflammation like IL-1a. It is expected that the clinical development of the program will help in developing the treatment protocols for multiple diseases like acne, diabetes, cardiovascular issues, cancer cachexia, psoriasis and others that lack a specific and effective treatment protocol. The company is also revolutionizing therapeutic systems to deliver biological therapies.
Over the years, the Texas-based company has developed a commercialized path for its lead product — the True Human antibody platform — by using disposable bioreactor technology and minimal infrastructure.